Real-time Price Updates for Biontech Se ADR (BNTX-Q), along with buy or sell indicators, analysis, charts, historical performance, news and more. On Friday 09/06/ the closing price of the BioNTech (ADRs) share was $ on BTT. Compared to the opening price on Friday 09/06/ on BTT of $, this. News · Events & Presentations; Financials. Financials. SEC Filings · Annual Reports Stock Quote & Chart. NASDAQ: BNTX. $ 6. September PM EDT. Stock analysis for BioNTech SE (BNTX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. We're maintaining our $ per ADR fair value estimate for BioNTech following second-quarter results that put the firm on track to meet our full-year.
On average, Wall Street analysts predict that Biontech Se's share price could reach $ by Aug 27, The average Biontech Se stock price prediction. BioNTech SE (BNTX) has a Smart Score of 6 based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge Fund. Pfizer stock toppled Friday after the pharma giant reported mixed results for its BioNTech-partnered combination flu and Covid vaccine. Based on short-term price targets offered by 14 analysts, the average price target for BioNTech SE Sponsored ADR comes to $ The forecasts range from a. BioNTech Stock (NASDAQ: BNTX) stock price, news, charts, stock research, profile. NewsBioNTech SE ADRBNTX ; 08/23/24 · The FDA Approved New Covid Vaccines. Should You Get One? ; 05/06/24 · BioNTech Revenue Falls Sharply on Reduced Covid Vaccine. Key Data. Open $; Day Range - ; 52 Week Range - ; Market Cap $B; Shares Outstanding M; Public Float M. Based on analysts offering 12 month price targets for BNTX in the last 3 months. The average price target is $ with a high estimate of $ and a low. Research BioNTech's (Nasdaq:BNTX) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance and more. Press Releases · 5 September BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress · 22 August. BNTX stock results show that BioNTech missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. Get Biontech SE (BNTX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. BioNTech SE ADR ; Latest Dividend, $ ; Ex-Dividend Date, Jun 2, ; Beta, ; Short Interest, M (08/15/24) ; Short Interest Change, %. BioNTech (BNTX) News Today BioNTech SE (NASDAQ:BNTX) Shares Purchased by Candriam S.C.A. HC Wainwright restated a "buy" rating and set a $ price. BioNTech Se Company Info. BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. European Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading · BioNTech to Present Clinical Data Updates Across mRNA and. Discover real-time BioNTech SE American Depositary Share (BNTX) stock prices, quotes, historical data, news, and Insights for informed trading and. BioNTech Earnings Beat. Pfizer's Vaccine Partner Battles Covid Downturn. BioNTech Stock Falls. The Covid Vaccine Maker Misses Revenue Estimates. View BioNTech SE Sponsored ADR BNTX stock quote prices, financial information, real-time forecasts, and company news from CNN.
Last quarter Biontech Se - American Depositary Shares reported $ million in Revenue and -$ earnings per share. This fell short of revenue expectation by. Get Biontech SE (BNTX.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments. BioNTech SE News & Analysis · Tempus and BioNTech team up to advance cancer therapies · Tempus AI Announces Real World Data Collaboration with BioNTech · US FDA. Stocks: 15 20 minute delay (Cboe BZX is real-time), ET. Volume reflects consolidated markets. Futures and Forex: 10 or 15 minute delay, CT. Market Data powered. BioNTech ADR (BNTX) - Germany based Co that develops commercializes personalized immunotherapies for the treatment of cancer.
Biotech boom ahead in 2024, top Jefferies analyst predicts on heels of Bristol Meyers-Karuna deal
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNTb2, BNT